HJ Science Co., Ltd.
6132.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.59B
Close$
$-0.51
101.5% downside
Current Fair Value
101.5% downsideOvervalued by 101.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.59 Billion |
|---|---|
| Enterprise Value | $1.34 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.83 |
| Beta | -0.15 |
| Outstanding Shares | 60,601,036 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -25.35 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 1.53 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About HJ Science Co., Ltd.
113 employees
CEO: Jian Xin Ji HJ Science Co., Ltd. is a clinical stage biotech company, which engages in research and development of small molecule drugs for tumors, autoimmune & metabolic system diseases for clinical treatments. It provides drug design, in vivo and ...